Profound Medical Completes $6.45 Million Private Placement to Expand Operations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy PROF?
Source: Globenewswire
- Successful Financing: Profound Medical has completed a private placement to Canadian investors, issuing 921,428 common shares at $7 each, raising approximately $6.45 million, which enhances the company's financial strength for future growth.
- Clear Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, indicating the company's commitment to market and technological innovation.
- Compliance Assurance: The securities issued are not registered under U.S. securities laws and are subject to a four-month hold period, ensuring the company operates within a compliant framework to mitigate legal risks.
- Broad Technological Prospects: Profound's TULSA-PRO system and Sonalleve platform show significant potential in the non-invasive treatment sector, with ongoing technological innovation and market expansion expected to enhance the company's competitiveness in the medical device industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PROF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PROF
Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is 11.67 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.320
Low
11.00
Averages
11.67
High
12.00
Current: 6.320
Low
11.00
Averages
11.67
High
12.00
About PROF
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mount Sinai Performs First AI-Powered Prostate Treatment, Enhancing Patient Quality of Life
- Successful First Treatment: Mount Sinai Hospital has successfully performed its first TULSA-PRO® prostate cancer treatment, establishing its leadership in robotic surgical care, with the patient discharged the same day, demonstrating the efficiency and safety of the procedure.
- Technological Innovation: The TULSA Procedure™ employs robotically controlled ultrasound to precisely heat prostate tissue to 55-57°C, ensuring no bleeding or hospital stay while maximizing protection of patient nerves and physiological functions, thereby reducing postoperative side effects.
- Clinical Application Prospects: This technology is applicable not only for prostate cancer patients but also effectively treats benign prostatic hyperplasia (BPH), providing patients with more optimal treatment options and paving the way for future research and guideline development.
- Market Potential: Profound Medical's TULSA-PRO® system is CE marked and FDA 510(k) cleared, expected to become a mainstream treatment option for prostate diseases, addressing the growing market demand.
See More
Profound Medical Completes $6.45 Million Private Placement to Expand Operations
- Successful Financing: Profound Medical has completed a private placement to Canadian investors, issuing 921,428 common shares at $7 each, raising approximately $6.45 million, which enhances the company's financial strength for future growth.
- Clear Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, indicating the company's commitment to market and technological innovation.
- Compliance Assurance: The securities issued are not registered under U.S. securities laws and are subject to a four-month hold period, ensuring the company operates within a compliant framework to mitigate legal risks.
- Broad Technological Prospects: Profound's TULSA-PRO system and Sonalleve platform show significant potential in the non-invasive treatment sector, with ongoing technological innovation and market expansion expected to enhance the company's competitiveness in the medical device industry.
See More
Profound Medical Corp. Raises $6.45 Million in Expanded Private Placement
- Increased Financing Size: Profound Medical Corp. has expanded its private placement to raise $6.45 million by issuing 921,428 common shares at $7 each, reflecting strong interest from long-term investors.
- Clear Use of Proceeds: The net proceeds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, aimed at enhancing the company's market competitiveness and innovation capabilities.
- Compliance Considerations: The securities offered will not be sold to U.S. purchasers, ensuring compliance with U.S. securities laws and reducing legal risks associated with the offering.
- Optimistic Market Outlook: Profound Medical focuses on developing incision-free treatment technologies, particularly the TULSA-PRO system, which is expected to drive growth in its market share within the prostate disease treatment sector.
See More
Profound Medical Raises $6.45 Million in Expanded Private Placement for Business Growth
- Increased Offering Size: Profound Medical has expanded its private placement to raise $6.45 million by issuing 921,428 common shares at $7 each, accommodating participation from a long-term investor, thereby enhancing liquidity.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, aiming to strengthen the company's competitive position in the medical device market.
- Compliance Statement: No securities will be sold to U.S. purchasers under this offering, ensuring compliance with U.S. securities laws, which mitigates legal risks and protects the interests of both the company and its investors.
- Technological Background: Profound Medical focuses on developing AI-powered, incision-free therapies, with the TULSA-PRO system poised to become a mainstream treatment option for prostate diseases, enhancing patient quality of life and driving long-term growth for the company.
See More
Profound Medical Corp. Raises $40 Million Through Share Offering at $7 Each
- Funding Scale: Profound Medical Corp. is raising up to $40 million through a registered direct offering of 5,142,857 common shares at $7 each, demonstrating strong market appeal and investor confidence.
- Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, and strategic transactions, aimed at enhancing the company's competitive edge and innovation capabilities to drive future growth.
- Private Placement Plan: The company also plans a private placement of up to 571,428 shares at $7 each to raise an additional $4 million, expected to close by December 30, showcasing flexible capital management.
- Market Reaction: The offering, led by healthcare-focused investors, is anticipated to close on December 22, reflecting strong investor confidence in Profound's future development.
See More
Profound Medical Receives RSNA Cum Laude Award, TULSA Procedure Significantly Reduces Patient Recovery Time
- Honor Recognition: Profound Medical's Dr. Pejman Ghanouni received the Cum Laude award at the 2025 RSNA Annual Meeting for his research on the TULSA procedure, highlighting the company's academic influence in prostate cancer treatment and enhancing its brand reputation.
- Clinical Data Advantage: The TULSA procedure allows patients to return to normal activities the day after treatment, compared to nearly three weeks for traditional robotic prostatectomy patients, significantly improving patient experience and potentially driving market demand.
- CAPTAIN Trial Results: The CAPTAIN trial recruited 210 patients across 20 sites in the U.S. and beyond, with 69% receiving the TULSA procedure, providing robust clinical data that further validates TULSA's safety and efficacy.
- Technological Innovation: The TULSA-PRO system integrates real-time MRI and AI technology to deliver personalized therapy, ensuring precise ablation of prostate tissue, marking a significant advancement in prostate disease treatment that could reshape the industry landscape.
See More
Mount Sinai Performs First AI-Powered Prostate Treatment, Enhancing Patient Quality of Life
- Successful First Treatment: Mount Sinai Hospital has successfully performed its first TULSA-PRO® prostate cancer treatment, establishing its leadership in robotic surgical care, with the patient discharged the same day, demonstrating the efficiency and safety of the procedure.
- Technological Innovation: The TULSA Procedure™ employs robotically controlled ultrasound to precisely heat prostate tissue to 55-57°C, ensuring no bleeding or hospital stay while maximizing protection of patient nerves and physiological functions, thereby reducing postoperative side effects.
- Clinical Application Prospects: This technology is applicable not only for prostate cancer patients but also effectively treats benign prostatic hyperplasia (BPH), providing patients with more optimal treatment options and paving the way for future research and guideline development.
- Market Potential: Profound Medical's TULSA-PRO® system is CE marked and FDA 510(k) cleared, expected to become a mainstream treatment option for prostate diseases, addressing the growing market demand.
See More
Profound Medical Completes $6.45 Million Private Placement to Expand Operations
- Successful Financing: Profound Medical has completed a private placement to Canadian investors, issuing 921,428 common shares at $7 each, raising approximately $6.45 million, which enhances the company's financial strength for future growth.
- Clear Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, indicating the company's commitment to market and technological innovation.
- Compliance Assurance: The securities issued are not registered under U.S. securities laws and are subject to a four-month hold period, ensuring the company operates within a compliant framework to mitigate legal risks.
- Broad Technological Prospects: Profound's TULSA-PRO system and Sonalleve platform show significant potential in the non-invasive treatment sector, with ongoing technological innovation and market expansion expected to enhance the company's competitiveness in the medical device industry.
See More
Profound Medical Corp. Raises $6.45 Million in Expanded Private Placement
- Increased Financing Size: Profound Medical Corp. has expanded its private placement to raise $6.45 million by issuing 921,428 common shares at $7 each, reflecting strong interest from long-term investors.
- Clear Use of Proceeds: The net proceeds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, aimed at enhancing the company's market competitiveness and innovation capabilities.
- Compliance Considerations: The securities offered will not be sold to U.S. purchasers, ensuring compliance with U.S. securities laws and reducing legal risks associated with the offering.
- Optimistic Market Outlook: Profound Medical focuses on developing incision-free treatment technologies, particularly the TULSA-PRO system, which is expected to drive growth in its market share within the prostate disease treatment sector.
See More
Profound Medical Raises $6.45 Million in Expanded Private Placement for Business Growth
- Increased Offering Size: Profound Medical has expanded its private placement to raise $6.45 million by issuing 921,428 common shares at $7 each, accommodating participation from a long-term investor, thereby enhancing liquidity.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, aiming to strengthen the company's competitive position in the medical device market.
- Compliance Statement: No securities will be sold to U.S. purchasers under this offering, ensuring compliance with U.S. securities laws, which mitigates legal risks and protects the interests of both the company and its investors.
- Technological Background: Profound Medical focuses on developing AI-powered, incision-free therapies, with the TULSA-PRO system poised to become a mainstream treatment option for prostate diseases, enhancing patient quality of life and driving long-term growth for the company.
See More
Profound Medical Corp. Raises $40 Million Through Share Offering at $7 Each
- Funding Scale: Profound Medical Corp. is raising up to $40 million through a registered direct offering of 5,142,857 common shares at $7 each, demonstrating strong market appeal and investor confidence.
- Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, and strategic transactions, aimed at enhancing the company's competitive edge and innovation capabilities to drive future growth.
- Private Placement Plan: The company also plans a private placement of up to 571,428 shares at $7 each to raise an additional $4 million, expected to close by December 30, showcasing flexible capital management.
- Market Reaction: The offering, led by healthcare-focused investors, is anticipated to close on December 22, reflecting strong investor confidence in Profound's future development.
See More
Profound Medical Receives RSNA Cum Laude Award, TULSA Procedure Significantly Reduces Patient Recovery Time
- Honor Recognition: Profound Medical's Dr. Pejman Ghanouni received the Cum Laude award at the 2025 RSNA Annual Meeting for his research on the TULSA procedure, highlighting the company's academic influence in prostate cancer treatment and enhancing its brand reputation.
- Clinical Data Advantage: The TULSA procedure allows patients to return to normal activities the day after treatment, compared to nearly three weeks for traditional robotic prostatectomy patients, significantly improving patient experience and potentially driving market demand.
- CAPTAIN Trial Results: The CAPTAIN trial recruited 210 patients across 20 sites in the U.S. and beyond, with 69% receiving the TULSA procedure, providing robust clinical data that further validates TULSA's safety and efficacy.
- Technological Innovation: The TULSA-PRO system integrates real-time MRI and AI technology to deliver personalized therapy, ensuring precise ablation of prostate tissue, marking a significant advancement in prostate disease treatment that could reshape the industry landscape.
See More
